Literature DB >> 4356680

Improved sensitivity in the measurement of estrogen receptor in human breast cancer.

W L McGuire, M DeLaGarza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4356680     DOI： 10.1210/jcem-37-6-986

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  26 in total

Review 1.  The Ishikawa cells from birth to the present.

Authors:  Masato Nishida
Journal:  Hum Cell       Date:  2002-09       Impact factor: 4.174

2.  Oestrogen receptors in breast cancer: a changing concept.

Authors:  G Leclercq; J C Heuson; M C Deboel; W H Mattheiem
Journal:  Br Med J       Date:  1975-01-25

3.  Immunohistochemical analysis of breast cancer oestrogen receptor status and its correlation with oestrogen receptor biochemical assay.

Authors:  P Johnston; P Dervan; M McAllister; M J Duffy; D N Carney
Journal:  Ir J Med Sci       Date:  1988-07       Impact factor: 1.568

4.  Specific polypeptide differences in normal versus malignant human breast tissues by two-dimensional electrophoresis.

Authors:  P J Wirth; V Egilsson; V Gudnason; S Ingvarsson; S S Thorgeirsson
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

5.  Eight-year follow-up of adjuvant therapy for stage II breast cancer.

Authors:  C A Hubay; N H Gordon; O H Pearson; J S Marshall; W L McGuire
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

6.  Quality control for estrogen receptor quantification by dextran-coated charcoal assay: a single laboratory's experience.

Authors:  S Raam; R Gelman; J Faulkner; G M White; J L Cohen
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

7.  Quantitation of oestrogen receptors: use of solid-phase antisteroid antibodies to quantify binding sites and determination of dissociation constant.

Authors:  S Raam; J L Cohen
Journal:  J Clin Pathol       Date:  1980-04       Impact factor: 3.411

8.  Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.

Authors:  D Cunningham; T J Powles; M Dowsett; G Hutchison; A M Brodie; H T Ford; J C Gazet; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Growth factor expression in normal, benign, and malignant breast tissue.

Authors:  M T Travers; P J Barrett-Lee; U Berger; Y A Luqmani; J C Gazet; T J Powles; R C Coombes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-11

10.  Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.

Authors:  O H Pearson; C A Hubay; J S Marshall; N H Gordon; W L McGuire; E G Mansour; R E Hermann; J C Jones; W J Flynn; C Eckert
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.